lipid

Grandbrothers/iStock Editorial via Getty Images Ionis Pharmaceuticals (NASDAQ:IONS) traded higher Tuesday after the U.S. FDA accepted to review a marketing application for its anti-lipid therapy olezarsen, targeted at a rare genetic condition known as familial chylomicronemia syndrome (FCA). Granting priority review for Ionis’ (IONS) New Drug Application (NDA) for olezarsen,Continue Reading